" class="no-js "lang="en-US"> Istesso - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Istesso | PTF

Istesso

About Istesso

Istesso

Istesso is a drug discovery and development company working in the field of immunometabolism. Our pipeline of pre-clinical and clinical assets act by reprogramming metabolism to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and multiple sclerosis. Istesso was founded in 2017 as the holding company for Modern Biosciences Ltd.

Related Story

Drug Development

 Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320 | PTF

Istesso Announces FDA Fast Track and Orphan Drug Designation for MBS2320

December 5 2022

Istesso Limited, the immunometabolism drug discovery and development company, has announced that the US Food […]